乳腺癌放疗后心脏辐射剂量与亚临床冠状动脉疾病进展:EARLY-HEART研究2年心脏CT结果
本研究为前瞻性多中心EARLY-HEART研究的二次分析,纳入224例无症状乳腺癌术后放疗患者,在放疗前和24个月时行心脏CT。结果显示较高的心脏辐射剂量与冠状动脉钙化(CAC)进展相关,尤其在已有钙化的患者中,而冠状动脉狭窄进展与剂量无关,但与基线CACS和CAC进展强烈相关。
要点
- 放疗后24个月CAC评分较基线升高,高剂量组CAC进展更明显。
- 已有钙化的患者中,心脏辐射剂量与CAC进展的关联更强。
- 冠状动脉狭窄进展与心脏辐射剂量无关,而与基线CACS和CAC进展相关。
关键影像表现/征象
- T24时CACS高于T0(中位数0 [IQR 0-25] vs 0 [IQR 0-17],P < .001)。
- 在T24时CAC评分大于0的88例参与者中,心脏辐射剂量最高四分位组较其余参与者CACS从T0增加更多(全心脏平均剂量,P < .001)。
- CAC进展超过队列中位数(16例参与者)的比例在最高辐射剂量组更高(相对风险:全心脏2.0 [95% CI: 1.5, 2.8];左心室1.8 [95% CI: 1.2, 2.5];右心室1.7 [95% CI: 1.2, 2.5];左前降支1.5 [95% CI: 1.0, 2.3])。
- 冠状动脉CTA上冠状动脉狭窄进展(36/224)与心脏辐射剂量无关,但与较高的基线CACS和较大的CAC进展强烈相关(均P < .001)。
诊断标准与关键数值
- CAC进展定义为T0至T24非对比CT上CAC评分的变化。
- 狭窄进展采用冠状动脉CTA的CAD-RADS分类评估。
- 心脏辐射剂量采用平均剂量和基于体积的指标量化全心脏、左心室、右心室和左前降支的剂量。
临床应用与阅片要点
- 对乳腺癌放疗后患者进行心脏CT随访时,应关注CAC进展,尤其在高心脏辐射剂量和已有钙化的患者中。
- 冠状动脉狭窄进展与辐射剂量无关,阅片时需结合基线CACS和CAC进展综合评估。
局限性
- 本研究为二次分析,样本量224例,随访仅24个月。
- 研究仅纳入女性乳腺癌患者,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To evaluate the relationship between cardiac radiation dose and progression of subclinical coronary artery disease using cardiac CT at baseline and 24 months after breast cancer radiation therapy. Materials and Methods This secondary analysis of the prospective multicenter EARLY-HEART study (ClinicalTrials.gov identifier: NCT03297346) included asymptomatic participants with breast cancer treated with radiation therapy after lumpectomy who underwent cardiac CT before radiation therapy (T0) and at 24-month follow-up (T24). Cardiac radiation dose to the whole heart, left ventricle, right ventricle, and left anterior descending coronary artery was quantified using mean dose and volume-based metrics. Coronary artery calcium (CAC) progression was assessed as changes in CAC score between T0 and T24 at noncontrast CT, and stenosis progression was assessed at coronary CT angiography using Coronary Artery Disease Reporting and Data System classification. Associations between cardiac radiation dose and imaging-based progression were evaluated using multivariable linear and logistic regression models adjusted for cardiovascular risk factors. Results The final analysis included 224 participants (58.4 years ± 8.0; all female participants). CACS was higher at T24 than at T0 (median, 0 [IQR, 0-25] vs 0 [IQR, 0-17]; P < .001). Among 88 participants with CAC scores greater than 0 at T24, CACS increased more from T0 in the highest quartile of cardiac radiation dose compared with the remaining participants (whole heart mean dose, P < .001). The proportion of participants with CAC progression above the cohort median (16 participants) was also greater in those receiving the highest radiation doses (relative risk: whole heart, 2.0 [95% CI: 1.5, 2.8]; left ventricle, 1.8 [95% CI: 1.2, 2.5]; right ventricle, 1.7 [95% CI: 1.2, 2.5]; left anterior descending coronary artery, 1.5 [95% CI: 1.0, 2.3]). In contrast, progression of coronary stenosis at coronary CT angiography (36 of 224) was not associated with cardiac radiation dose but was strongly associated with higher baseline CACS and greater CAC progression (both P < .001). Conclusion Higher cardiac radiation dose during breast cancer radiation therapy was associated with increased CAC progression at 2-year follow-up, particularly in participants with preexisting calcification, whereas coronary stenosis progression was unrelated to dose. Keywords: Radiotherapy, Cardiac CT, Atherosclerosis, Coronary Artery Plaque Supplemental material is available for this article. ClinicalTrials.gov identifier: NCT03297346 © RSNA, 2026.
引用
- Mousseaux E, Craiem D, Vliegenthart R, et al. Cardiac Radiation Dose and Subclinical Coronary Artery Disease Progression after Breast Cancer Radiotherapy: 2-year Cardiac CT Results from the EARLY-HEART Study. Radiol Cardiothorac Imaging. 2026. PMID: 42165741. doi:10.1148/ryct.250342
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。